California Public Employees Retirement System Has $29.50 Million Holdings in Illumina, Inc. $ILMN

California Public Employees Retirement System boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 309,145 shares of the life sciences company’s stock after purchasing an additional 17,439 shares during the period. California Public Employees Retirement System’s holdings in Illumina were worth $29,496,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ILMN. WCM Investment Management LLC lifted its holdings in shares of Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P raised its holdings in Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares during the period. Corvex Management LP raised its holdings in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after buying an additional 2,129,449 shares during the period. Geode Capital Management LLC lifted its stake in Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after buying an additional 21,342 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Illumina by 361.7% in the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after buying an additional 1,662,093 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research reports. UBS Group boosted their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Cowen restated a “hold” rating on shares of Illumina in a report on Friday, October 31st. Evercore ISI upped their price objective on Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, TD Cowen lifted their target price on Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $115.00.

Illumina Price Performance

NASDAQ:ILMN opened at $134.91 on Thursday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $153.06. The company has a market cap of $20.61 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.36 and a beta of 1.44. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The stock’s 50-day simple moving average is $113.32 and its 200 day simple moving average is $102.00.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business’s revenue was up .4% compared to the same quarter last year. During the same period last year, the company earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.